Brand TransitionThe company is nearly done with its brand transition in the U.S. and Canada, and is progressing on pipeline initiatives such as pen needles for generic GLP-1 administration.
Debt ReductionEMBC reported a $17M beat for F3Q and reached its annual goal of $110M debt paydown a quarter ahead of its expectations.
Financial PerformanceEmbecta reported F3Q revenue of $295.5M, $17M above consensus, with pricing and volume benefits contributing equally to the outperformance.